Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213199 · ClinicalTrials.gov registry record · Phase 2
Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01213199 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 20 participants.
The verdict
NCT01213199, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.
Interventions
- DRUG Adapalene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213199
The ClinicalTrials.gov registry entry for NCT01213199 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adapalene is the first listed.
NCT01213199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213199 about?
NCT01213199 is a clinical study titled "Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars". The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.
What is the current status of trial NCT01213199?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01213199?
The interventions under investigation include: Adapalene (DRUG).
Who is sponsoring clinical trial NCT01213199?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.